Metraipolis › archive › dc_60d8cea00941
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells — Europe PMC PMID:32633234
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32633234
- DOI
- 10.7554/elife.54854
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-08T06:03:47.027Z
- SHA-256 of the archived text
dd5eb663b527fd182e440cb17fcb016be145a9e1c2d1e7e238488f20f7d5f425- Stable URL of this page
https://metraipolis.com/documento/dc_60d8cea00941
How to cite
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells — Europe PMC PMID:32633234 — Europe PMC (en), https://europepmc.org/article/MED/32633234 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_60d8cea00941 (Metraipolis archive dc_60d8cea00941, sha256 dd5eb663b527fd182e440cb17fcb016be145a9e1c2d1e7e238488f20f7d5f425)
BibTeX
@misc{dc60d8cea00941,
title = {Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells — Europe PMC PMID:32633234},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32633234},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_60d8cea00941; sha256 dd5eb663b527fd182e440cb17fcb016be145a9e1c2d1e7e238488f20f7d5f425},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32633234. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. This approach may still be limited by the presence of immunosuppressive myeloid populations. Here, we demonstrate that NK cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. Treatment of xenograft tumors resulted in PD-L1-dependent tumor growth inhibition. PD-L1 CAR haNKs reduced levels of macrophages and other myeloid cells endogenously expressing high PD-L1 in peripheral blood from patients with head and neck cancer. The clinical study of PD-L1 CAR haNKs is warranted. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: eLife, 2020 (prima pubblicazione 2020-07-07). Identificativi: PMID 32633234 · PMCID PMC7340502 · DOI 10.7554/elife.54854. Parole chiave degli autori: Human; Mouse; Inflammation; NK cells; Myeloid; PD-L1; immunology; xenograft; Syngeneic; Chimerica Antigen Receptor. Pagina: https://europepmc.org/article/MED/32633234 — https://doi.org/10.7554/elife.54854. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-08T05:59:09.946Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.